

Gene therapies market is projected to reach USD 14.6 billion in 2030, growing at a CAGR of 30%, claims Roots Analysis

Driven by the potential treat the root cause of diseases, the gene therapies pipeline is growing, and the market anticipated to witness substantial growth

LONDON, UNITED KINGDOM, February 3, 2021 /EINPresswire.com/ -- [Roots Analysis](https://www.rootsanalysis.com/) has announced the addition of [“Gene Therapy Market \(4th Edition\), 2020-2030”](https://www.rootsanalysis.com/reports/view-document/gene-therapies-market/268.html) report to its list of offerings.

Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.

To order this 720+ page report, which features 220+ figures and 375+ tables, please visit <https://www.rootsanalysis.com/reports/view-document/gene-therapies-market/268.html>

Key Market Insights

Roots Analysis

BUSINESS RESEARCH & CONSULTING

Roots Analysis

Example highlights
The gene therapy market is characterized by a healthy drug pipeline, with 10 approved molecules and over 820 product candidates being evaluated for the treatment of multiple disease indications, worldwide

Gene Therapies: Development Pipeline

S. No.	Drug Name	Phase	Developer(s)	Target Indication	Therapeutic Area	Special Designation(s)	Awarded	Vector	Gene	Therapeutic Approach	Type of Therapy
13	Luxturna*	Approved	Spark	Biallelic RPE65-mediated RD	Ophthalmic Disease	Orphan drug, breakthrough therapy, rare pediatric disease		AAV2	RPE65	Gene Augmentation	In vivo
67	OTL-200	Phase III	Ochard therapeutics	Metachromatic leukodystrophy	Genetic Disorder	Orphan drug, rare pediatric disease		Lentivirus	ARSA	Gene Augmentation	Ex vivo
115	RP-L102	Phase II	rocket	Fanconi Anemia	Genetic Disorder	PRIME, RMAT, fast track, rare pediatric disease, orphan drug		Lentivirus	FANCA	Gene Augmentation	Ex vivo
279	EB-101	Phase III	Abeona	Recessive dystrophic epidermolysis bullosa	Dermatological Disorder	Orphan drug, breakthrough therapy, rare pediatric disease, RMAT		Retrovirus	COL7A1	Gene Augmentation	Ex vivo
370	AAV-GAD	Phase II	MEIRAGT	Parkinson's disease	Nervous System Disorder						
432	Engismo®	Phase I	HELIUMITH	Coronary artery disease	Cardiovascular Disease						
505	RP-323	Phase III	PhorMed	COVID-19	Infectious Disease						

Information on 530+ early stage products and 270+ clinical stage drugs is available in the report

Gene Editing Portfolio

S. No.	Drug Name	Phase	Developer(s)	Indication	Therapeutic Area
15	SB-318	Phase III	Sangamo	Mucopolysaccharidosis type 1	Metabolic Disorder
45	LB-201	Discovery	LogicBio	Alpha-1 antitrypsin deficiency	Metabolic Disorder
62	Unnamed	Discovery	Beigene	Stargardt Disease	Ophthalmic Disease

Information on 70+ gene editing therapies is available in the report

Abbreviations: RD - inherited retinal disease, AAV2 - Adeno-associated virus, RMAT - Regenerative medicine advanced therapy designation. Note: * Industry claims have been independently validated; newly approved molecules less than 01 employees, mid-sized 01-500 employees, large companies 501-1,000 employees and very large companies 1,000+ employees on the basis of employee count.

Developer Landscape: Distribution by Company Size and Geography*

Gene Therapies Pipeline

Example highlights
Foreseeing a lucrative returns, many public and private investors have made investments worth over USD 25 billion, across more than 350 instances, in the period between 2015 and 2020

Funding and Investments
Distribution by Year, Amount Invested and Type of Funding

Funding and Investments
Distribution of Amount Invested by Geography

Key Players
China, Israel, Japan, South Korea

Note: For 2020, funding instances have been captured till mid-August 2020


Around 800 gene therapies are currently being developed across different stages. Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of development (discovery / preclinical), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of clinical stage candidates are intended for the treatment of oncological disorders.

Over 65% of innovator companies focused on gene therapy development, are based in North America. Interestingly, more than 75 players based in the same region, are start-ups, while over 35 are mid-sized players, and 10 are large and very large firms. Since the majority of gene therapy developers are headquartered in the US, it is considered a key R&D hub for such advanced therapy medicinal products.


There are 400+ registered gene therapy focused clinical trials, worldwide. Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 12% during the period 2015-2020. Of the total number of trials, close to 25% have already been completed, and 35% claim to be actively recruiting.

USD 25.4 billion has been invested by both private and public investors, since 2015. So far, a significant portion of the capital raised has been through secondary offerings (USD 12.9 billion). On the other hand, around USD 5 billion was invested by venture capital investors, representing 20% of the total amount.

Close to 20,000 patents have been filed / published related to gene therapies, since 2016. Around 30% of the total number of applications were related to gene editing-based therapies, while the remaining were associated with gene therapies. Further, majority of the patent assignees were industry players, however, the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 16%), over the past few years.



Gene Therapies - Cost Price Analysis



Gene Therapies Market

There have been several mergers and acquisitions in this market during the period 2015-2019. In fact, M&A activity is reported to have increased at a CAGR of more than 40%. Key drivers of the acquisitions mentioned in the report include, therapeutic area expansion, access to a novel technology / platform, drug class consolidation and drug class expansion.

North America and Europe are anticipated to capture over 90% of the market share, in terms of sales revenues, in 2030.

In vivo gene therapies currently represent a significant share of the market, and this trend is unlikely to change in the foreseen future, as several such candidates are being evaluated in late stages. In addition, more than 130,000+ patients are projected to use gene therapies in 2030 and the demand for gene therapies is expected to grow at an annualized rate of 29% and 31% during the periods 2020-2025 and 2025-2030, respectively.

To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

Key Questions Answered

Who are the leading players engaged in the development of gene therapies?

How many gene therapies are presently being evaluated across different stages of development?

What are various diseases targeted by gene therapies?

What are the key technology platforms that are either available, or being developed for gene therapy discovery and production?

What kind of vectors are commonly used for the delivery of gene therapies?

What are the key regulatory guidelines governing the approval of gene therapies, across various geographies?

What kind of pricing models and reimbursement strategies are currently used by gene therapy developers?

What kind of contract services are offered related to gene therapies? Who are the key players in this market?

What are the drivers of the M&A activity in this market?

What kind of investors have stake in the gene therapy market?

What kind of commercialization strategies are used by gene therapy developers?

How is the current and future market opportunity likely to be distributed across key market segments?

The USD 14.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

Therapeutic approach

Gene augmentation

Oncolytic therapy

Immunotherapy

Others

Type of gene therapy

Ex vivo

In vivo

Type of vector used

Adeno associated virus

Adenovirus

Herpes simplex virus

Lentivirus

Plasmid DNA

Retrovirus

Others

Key therapeutic areas

Autoimmune disorders

Cardiovascular diseases

Dermatological disorders

Genetic disorders

Hematological disorders

Metabolic disorders

Muscle-related diseases

Oncological disorders

Ophthalmic diseases

Others

Route of administration

Intraarticular

Intracerebellar

Intradermal

Intramuscular

Intratumoral

Intravenous

Intravesical

Intravitreal

Subretinal

Others

Key geographical regions

North America

Europe

Asia-Pacific

The report features inputs from eminent industry stakeholders, according to whom, gene therapies exhibit the potential to become a promising alternative for the treatment of genetic disorders. The report includes detailed transcripts of discussions held with the following experts:

Adam Rogers (CEO, Hemera Biosciences)

Al Hawkins (CEO, Milo Biotechnology)

Buel Dan Rodgers (Founder & CEO, AAVogen)

Christopher Reinhard (CEO & Chairman, Gene Therapeutics (previously known as Cardium Therapeutics))

Michael Triplett (ex-CEO, Myonex Therapeutics)

Robert Jan Lamers (ex-CEO, Arthrogen)

Ryo Kubota (CEO, Chairman & President, Acucela)

Tom Wilton (ex-CBO, LogicBio Therapeutics)

Jeffrey Hung (CCO, Vigene Biosciences)

Cedric Szpirer (Executive & Scientific Director, Delphi Genetics)

Marco Schmeer (Project Manager) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory)

Molly Cameron (Corporate Communications Manager, Orchard Therapeutics)

The research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration, and recent developments (if available).

Abeona Therapeutics

Advantagene

Biogen

bluebird bio

Castle Creek Biosciences

CG Oncology

FerGene

Freeline Therapeutics

Gradalis

Helixmith

Inovio Pharmaceuticals

Kolon TissueGene

Krystal Biotech

Lysogene

Neurophth Therapeutics

OncoSec Immunotherapies

Orchard Therapeutics

Pfizer
Sangamo Therapeutics
Spark Therapeutics
uniQure Biopharma
VBL Therapeutics

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com

Gaurav Chaudhary
Roots Analysis
+1 415-800-3415
Gaurav.Chaudhary@rootsanalysis.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/535218785>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.